Life science platform iQ spaces is taking over the €180 mln development of the Berlin Center for Gene and Cell Therapies, in partnership with Bayer AG and Charité – Universitätsmedizin Berlin.
The project involves the construction of a modern, ten-story building with a gross floor area of 18,000 m2 on the Bayer Campus at Nordhafen. Construction is scheduled to begin in 2025.
The building will house an incubator with fully equipped lab and office space, as well as customizable rental space for 15 to 20 startups at various stages of development. In addition, a production area certified to Good Manufacturing Practice (GMP) standards will be integrated.
As part of the project, iQ spaces is responsible for the acquisition of the property, the development of the translation center and the leasing of the space.
iQ spaces, a subsidiary of Rockstone Capital Partners, specializes in the development and professional management of office, laboratory and production space for life science companies.
Vincent Wege, managing partner of iQ spaces, said: 'The development of this center for cell and gene therapies is an important milestone for Germany as a research location. We are proud to work with Bayer and Charité to create an environment that fosters innovation and bridges the gap between research and application.'
